Page 162 - Genentech News Today

A pancreatic cancer vaccine has proven to be effective in half of patients treated in a small trial, according to a study published in the journal Nature on Wednesday.

Current treatment strategies for patients with central nervous system vasculitis are not based on high-grade scientific evidence but rather expert opinion, according to a speaker at the Biologic Therapies Summit.“The treatment strategy is based on case series, retrospective studies and expert opinion,” Rula Hajj-Ali, MD, of the Cleveland Clinic, told attendees at the hybrid meeting.

The Supreme Court's consideration of the standards for satisfying the enablement provisions of 35 U.S.C. 112(a) has been occasioned for the first time in over a century by the Court's...

North Bethesda, Maryland (PRWEB) May 09, 2023 -- (North Bethesda, Maryland, USA, May 9, 2023) – ISPE today announced the 2023 Facility of the Year Awards

Unaudited Condensed Consolidated Statements of Loss and Other Comprehensive Income ... | May 10, 2023

Pieris Pharmaceuticals Reports First Quarter 2023 Financial Results ...

Using mRNA tailored to each patient’s tumor, the vaccine may have staved off the return of one of the deadliest forms of cancer in half of those who received it.

Enrollment ongoing in expansion portion of Phase 1/2 KB-0742 study, with initial efficacy data expected in 2H 2023 Phase 1b/2 study of lanraplenib in combination with gilteritinib in FLT3-mutated AML... | May 10, 2023

Operator: Good day and welcome to Revolution Medicines First Quarter 2023 Earnings Conference Call. As a reminder, todays conference is being recorded.

Acceptance based on two phase III studies that demonstrated early and sustained vision improvement with Vabysmo, meeting primary endpoint of non-inferiority compared to afliberceptApplication was... | May 9, 2023